Spartan Medical Associates
- Peptide Therapy
- Erectile Dysfunction (ED) Treatment
- Hormone Replacement Therapy (HRT)
- Testosterone Replacement Therapy (TRT)
Charlotte, NC
Charlotte has a banking and professional services hub with growing longevity demand, and peptide therapy has grown into a visible slice of the local wellness market. The clinics we track across SouthPark, Ballantyne, Dilworth, and Uptown range from physician-led longevity practices to medspa-adjacent wellness offices offering sermorelin blends and growth hormone peptides. Most local prescribers have training or admitting privileges within the Atrium Health, Novant, and Carolinas Medical network. The scene here skews toward physician-led clinics offering peptide plus HRT protocols to executives and relocated professionals. The regulatory landscape shifted sharply in 2023 and 2024 when the FDA placed several widely prescribed peptides on its Category 2 bulk substances list, restricting which ingredients compounding pharmacies could legally source. That changed access overnight for BPC-157, CJC-1295, ipamorelin, and thymosin beta-4. Sermorelin and tesamorelin remain FDA-approved for specific indications, and reputable Charlotte clinics now draw a clearer line between approved peptides and off-label research compounds than they did two years ago.
Regulatory context
Most research peptides used in regenerative medicine (BPC-157, TB-500, CJC-1295, ipamorelin) are not FDA-approved drugs. Sermorelin and tesamorelin hold FDA approvals for specific indications. The FDA placed several peptides into Category 2 on its Bulk Drug Substances Nominated for Use in Compounding list during 2023 and 2024, restricting 503A pharmacy sourcing. Section 503A covers traditional patient-specific compounding; Section 503B covers FDA-registered outsourcing facilities held to cGMP.
The North Carolina Board of Pharmacy inspects compounding facilities for USP compliance. Non-resident pharmacies shipping peptides into North Carolina must hold a current non-resident permit. The Board publishes public inspection reports and disciplinary actions.